Long periods of follow-up may be necessary for gene therapies, particularly if and when the US Food and Drug Administration is willing to grant a company an accelerated approval for such a treatment, FDA Commissioner Robert Califf said.
At the J.P. Morgan Healthcare Conference 10 January, Califf was asked for his assessment of what circumstances he envisions gene therapies being given accelerated approvals using surrogate endpoints and whether...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?